Insitro vs Pliant Therapeutics
Side-by-side comparison of AI visibility scores, market position, and capabilities
Drug discovery company founded by Daphne Koller integrating ML with high-throughput biology; raised $400M+ to build proprietary biological datasets for predicting drug targets and clinical outcomes in neurology, metabolic, and oncology programs.
About
Insitro is a drug discovery company founded in 2018 by Daphne Koller, a pioneer in machine learning and computational biology, having raised over $400M to build an integrated ML and biology platform. The company generates large-scale biological datasets using automated laboratory systems and human induced pluripotent stem cell models of disease, then trains machine learning models on this data to predict drug targets, patient stratification, and clinical outcomes. Unlike companies that apply ML to existing datasets, Insitro builds proprietary biological datasets specifically designed to train predictive models for drug discovery. The platform is being applied to neurological diseases, metabolic disorders, and oncology with the goal of identifying drug candidates more likely to succeed in clinical trials. Insitro has established partnerships with major pharmaceutical companies including Gilead Sciences and Bristol Myers Squibb to co-develop drugs using the platform. The company represents a model for how ML can be deeply integrated into pharmaceutical R&D rather than applied as a surface-level analytical layer.
Pliant Therapeutics is a clinical-stage biotech (Nasdaq: PLRX) developing integrin inhibitors for fibrotic diseases, with lead program bexotegrast in Phase 2b/3 trials for idiopathic pulmonary fibrosis.
About
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH/MASH). Integrins are cell surface receptors that activate TGF-β, the master regulator of fibrosis — blocking specific integrin subtypes (αvβ6, αvβ1) can halt or reverse fibrosis progression without broadly suppressing immunity.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.